Blue Matter’s Post

First synthesized in 1912 by Merck, the empathogenic drug 3,4-#Methylenedioxymethamphetamine (MDMA) is inching toward FDA approval following the positive results of a phase 3 study. The recently concluded phase 3 study, MAPP2 found that #MDMA-assisted therapy significantly outperforms traditional talk therapy in reducing #PTSD symptoms. MORE ON THIS HERE: https://lnkd.in/gqeUvQ_k #ClinicalTrials #PsychiatricDrugs #PsychotropicDrugs Multidisciplinary Association for Psychedelic Studies (MAPS)

The FDA has cleared Otsuka Pharmaceutical Companies (U.S.) and Click Therapeutics, Inc.' prescription #digitaltherapeutic (DTx) for treating major depressive disorder (MDD) symptoms. https://lnkd.in/dXesYgbu #biotechnology #ClickTherapeutics #depression #digitaltherapeutics #DTx #FDA #Otsuka #productapprovals #regulatoryaffairs

Ever wonder what happens to drug candidates when they do not meet expectations in clinical trials? This is the case for antipsychotic candidate Pimavanserin. Acadia Pharmaceuticals has made the decision to discontinue the development of their antipsychotic candidate following disappointing results in Phase III trials. While setbacks are part of the drug development process, this decision emphasizes the challenges in addressing the intricacies of mental health disorders. Read more about this development in the article below. #AcadiaPharmaceuticals | #SchizophreniaResearch | #ClinicalTrials | #DrugDevelopment | #MentalHealthAwareness | #HealthcareIndustry

Bionomics Surges as PTSD Drug Posts Positive Phase 2 Trial Results Bionomics is experiencing a significant rebound, with its shares surging nearly 200% due to promising phase 2 data in post-traumatic stress disorder (PTSD) treatment. The trial demonstrated substantial improvement in PTSD symptoms for participants receiving BNC210 compared to a placebo, meeting its primary endpoint. The drug also showed positive results in measures of depressive symptoms and sleep. While BNC210 had minor safety concerns, Bionomics plans to engage with the FDA to pursue drug approval for PTSD treatment, despite competition in the field. The market's renewed confidence is evident, but the stock still has ground to cover. If you're interested in continuing to read the full story and want to stay updated with the Latest Pharma News in USA, visit Pharmtales. #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #bionomics #ptsddrug #fda https://lnkd.in/gM4SuZMT

Thoughts on this? >> Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharmaceutical #pharma #healthcare #biotech

Thoughts on this? >> Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #competitivemarketing #healthcare

Thoughts on this? >> BMS' newly acquired schizophrenia drug showed continued symptom improvement in open-label studies >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #pharma #healthcare #biotech

Thoughts on this? >> BMS' newly acquired schizophrenia drug showed continued symptom improvement in open-label studies >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #competitivemarketing